2,134,591 Shares in Boston Scientific Corporation $BSX Acquired by Employees Provident Fund Board

Employees Provident Fund Board bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,134,591 shares of the medical equipment provider’s stock, valued at approximately $203,533,000. Boston Scientific comprises 1.5% of Employees Provident Fund Board’s investment portfolio, making the stock its 25th largest position.

A number of other large investors have also recently added to or reduced their stakes in the business. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth $26,000. Colonial Trust Co SC grew its holdings in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank raised its position in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock opened at $45.30 on Friday. The company has a market capitalization of $67.33 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 0.87 and a beta of 0.56. Boston Scientific Corporation has a 1-year low of $44.44 and a 1-year high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock’s fifty day simple moving average is $54.71 and its 200-day simple moving average is $73.03.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the prior year, the business earned $0.75 EPS. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Insider Activity

In related news, Director David C. Habiger acquired 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 9,800 shares of company stock worth $554,012 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

BSX has been the subject of several analyst reports. Bank of America reduced their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. Piper Sandler restated an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research note on Thursday, April 23rd. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Finally, Jefferies Financial Group cut their price target on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.